Drug Database
ZO

zolpidem tartrate (Intermezzo / zolpidem, TransOral)

✓ Approved

Transcept Pharmaceuticals · GABRA1 · Small Molecule

What is zolpidem tartrate?

zolpidem tartrate is a small molecule developed by Transcept Pharmaceuticals. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesIntermezzo, zolpidem, TransOral
CompanyTranscept Pharmaceuticals
Drug ClassSmall Molecule
Molecular TargetGABRA1
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Transcept Pharmaceuticals

Mechanism of Action

Molecular Targets

zolpidem tartrate acts on 1 molecular target:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

zolpidem tartrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersInsomnia✓ Approved

Related Research Articles

PubMedTherapeutic delivery2026-11-10

Functionalized nanocarrier-based intranasal drug delivery of rivastigmine tartrate for enhanced brain exposure: a pharmacokinetic and biodistribution evaluation.

Shetty Shravi S, Suvarna Vasanti V

To develop and evaluate a polyethylene glycol (PEG)-functionalized multi-walled carbon nanotube (MWCNT)-based intranasal delivery system for rivastigmine tartrate (RT) to improve systemic exposure and brain delivery for Alzheimer's disease (AD). RT-loaded PEGylated MWCNTs were prepared, optimized using a 32 factorial design, and characterized for particle size, zeta potential, entrapment efficiency, morphology, in vitro release, ex vivo nasal permeation, pharmacokinetics, brain biodistribution, cytocompatibility, and neuroprotective activity. The optimized formulation showed an entrapment efficiency of 90.92%, particle size of 176.7 nm, and zeta potential of -24.1 mV. Sustained drug release and efficient permeation across goat nasal mucosa were observed. Intranasal administration increased plasma exposure, producing approximately 5-fold higher relative bioavailability and a 4.1-fold increase in brain exposure compared with oral administration. In SH-SY5Y cells, the formulation reduced rotenone-induced oxidative stress and improved cell viability, indicating neuroprotective potential. PEGylated MWCNT-mediated intranasal delivery enhanced rivastigmine bioavailability and brain exposure while demonstrating neuroprotective activity in vitro. These findings support further investigation of this nanocarrier platform as a strategy for brain-targeted delivery of rivastigmine.

PMID 43004651
Read full article →
PubMedMicrobial cell factories2026-11-06

Amelioration of lipid production by Cunninghamella echinulata: statistical optimization and GC-MS characterization.

Abdou Hany A A HAA, Abdel-Sater Mohamed A MA, El-Shanawany Abdel-Rehim A A AAA, Hassane Abdallah M A AMA

Lipids have garnered attention for their importance in pharmaceuticals and nutraceuticals. Famously, oleaginous filamentous fungi produce essential fatty acids. In this study, optimization using one factor at time (OFAT) and response surface methodology-Box-Behnken design (RSM-BBD) approaches, Cunninghamella echinulata showed the highest lipid content (61.23%) under optimized OFAT conditions (60 g/L, glucose; 2 g/L; ammonium tartrate; pH value, 7 at 30 °C, and shaking for seven days). Lipid content of 59.37% was achieved using the BBD. One-way ANOVA indicated temperature significantly affected lipid content, while two-way ANOVA revealed significant interactions between temperature and ammonium tartrate concentration, pH and incubation time, and inoculum size and glucose concentration. Various agro-wastes used as media for C. echinulata growth and production of lipid with peach yielding the best lipid content (49.30%). Comparative analysis of lipid extracts by GC-MS of the best yield conditions revealed nineteen different fatty acids, with oleic acid, linoleic acid, gamma-linolenic acid, and palmitic acid present in high percentages of 35.49%, 21.31%, 21.78%, and 13.44%, respectively. The extracted lipids demonstrated antibacterial potential towards Staphylococcus aureus, Escherichia coli, and Bacillus subtilis, as well as antifungal efficacy against Candida albicans and C. glabrata. The inhibition zones ranged from 9 to 19 mm with 50 µL of 10% extracts (100 mg/mL). This investigation revealed that optimization of C. echinulata represents promising candidate for high lipid yield in addition to lipid extracts may serve as potential antimicrobial agents in the pharmaceutical industry.

PMID 42989300
Read full article →
PubMedChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026-11-06

Posterior fossa syndrome.

Toescu Sebastian M SM, Aquilina Kristian K, Klimo Paul P

Posterior fossa syndrome (PFS), also known as cerebellar mutism syndrome (CMS), is a distressing postoperative complication affecting children undergoing craniotomy for infratentorial tumors, most frequently medulloblastoma. It is characterized by a distinct latency period followed by mutism, profound emotional dysregulation, and a broad spectrum of cerebellar motor and cognitive deficits. Diffusion MRI and tractography have consistently shown that structural damage to the proximal efferent cerebellar pathway-specifically the dentato-rubro-thalamo-cortical tract within the superior cerebellar peduncle-is strongly implicated as the anatomical driver of PFS. Historical series favored the telovelar over the transvermian surgical approach, although recent prospective multicenter data demonstrate equivalent risks between the two techniques, shifting the neurosurgical focus toward meticulous surgical technique and minimizing damage to eloquent tissue around the fourth ventricle. Validated clinical scoring tools, such as the Posterior Fossa Syndrome Questionnaire, standardize clinical phenotyping and are making their way into clinical practice. Increasingly advanced risk prediction models allow for precise preoperative risk stratification based on objective imaging markers. Pharmacological interventions, including zolpidem and selective serotonin reuptake inhibitors, have shown limited efficacy in mitigating acute symptoms. Although near-universal clinical improvement occurs over time, long-term neurocognitive and motor sequelae remain highly disabling. Combining advanced neuroimaging, sophisticated risk modeling and meticulous microsurgical technique offers the best paradigm to shift the narrative of PFS from an expected complication to a preventable one.

PMID 42988926
Read full article →
PubMedBone2026-11-04

Procyanidin B2 ameliorates osteoporosis by modulating osteoclast precursor differentiation through activation of the PI3K/Akt/Nrf2 axis.

Zou Yanpei Y, Wang Chenyu C, Zhang Tianlong T, Huang Yining Y et al.

Osteoporosis (OP) is a chronic, systemic skeletal disorder characterized by excessive osteoclast activation and bone resorption, for which effective therapies with minimal adverse effects remain limited. Reactive oxygen species (ROS) generated during oxidative stress promote osteoclast differentiation and are considered a primary contributor to OP pathogenesis. Procyanidin B2 is a natural flavonoid with potent anti-inflammatory and antioxidant properties; however, its therapeutic efficacy and underlying mechanisms of action in OP remain unclear. In this study, we investigated the effects of procyanidin B2 on osteoclastogenesis using tartrate-resistant acid phosphatase staining, quantitative real-time polymerase chain reaction, and pit formation assays. Our findings indicate that procyanidin B2 inhibits RANKL-induced osteoclastogenesis in a dose-dependent manner. Mechanistically, procyanidin B2 activates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, thereby upregulating nuclear factor erythroid 2-related factor 2 (Nrf2) expression. This induction of Nrf2 enhances ROS clearance in osteoclast precursors (OCPs), leading to functional modulation of their differentiation trajectory rather than mere suppression of OCP proliferation. Moreover, micro-computed tomography and histological analyses reveal that procyanidin B2 alleviates ovariectomy-induced bone loss in mice and demonstrates favorable in vivo biocompatibility. Collectively, these findings indicate that procyanidin B2 mitigates OP by modulating OCP differentiation throughout activation of the PI3K/Akt/Nrf2 axis and highlight its potential as a novel natural therapeutic agent for the prevention and treatment of OP.

PMID 42982263
Read full article →
PubMedInternational journal of biological macromolecules2026-11-03

Structural basis for saccharide binding by human RNase 2/EDN: Insights into its potential lectin-like properties.

Kang Xincheng X, Prats-Ejarque Guillem G, Boix Ester E, Li Jiarui J

Human RNase 2, also named the eosinophil-derived neurotoxin (EDN), is a secretory protein of the vertebrate-specific RNase A superfamily involved in antiviral and proinflammatory cell response. Identifying ligand-binding pockets in EDN is thus relevant to structure-based drug design. By X-ray crystallography we first identified a conserved site at the protein surface binding to carboxylic anion molecules: malonate, tartrate and citrate. Searching for potential biomolecules rich in anion groups and considering previous report of EDN interaction to glycosaminoglycans, we explored the protein binding to saccharides. EDN crystals were soaked with mono- and disaccharides, and the 3D structures of ten complexes were solved by X-ray crystallography at atomic resolution. We identified protein bound ligands for glucose, fucose, mannose, galactose, trehalose, sucrose, N-acetyl-D-glucosamine, N-acetylmuramic acid, and the sialic acid N-acetylneuraminic acid. A main interaction site for glucose, fucose, and galactose was located adjacent to the spotted carboxylic anion site. Secondarily, N-acetylneuraminic acid and mannose shared another close by protein surface region. Overall, we located 17 saccharide ligands that clustered into seven defined sites, outlining an extended interaction interface, which was further analysed by molecular modelling. Interestingly, within the RNase A superfamily, we find amphibian RNases that were initially isolated as carbohydrate binding proteins and named as leczymes, combining enzymatic and lectin properties. The present data is the first structural characterization of putative sugar binding sites for a mammalian RNase family member. The results highlight unique EDN residues that can mediate sugar interactions, of potential interest to further explore the protein physiological role.

PMID 42977053
Read full article →
PubMedIndian journal of pharmacology2026-11-02

Aromadendrin attenuates dexamethasone-induced osteoporosis in rats by modulating oxidative stress, inflammation, and bone remodeling.

Ma Ru R, Li Xia X, Fuad Mohd Afiq Muhamed MAM, Lu Shuang S

Glucocorticoids (GCs) are used in the treatment of asthma, autoimmune and allergic disease, but long-term GC therapy increased the bone resorption, oxidative stress, inflammation, and impaired bone formation. Aromadendrin is a flavonol (flavonoid) exhibited the potent effect against oxidative stress and inflammatory disease. The aim of the experimental study was to investigate the antiosteoporosis effect of aromadendrin against dexamethasone (DEX) induced osteoporosis (OS) in the rats. Female Sprague Dawley rats were used in this study and subcutaneous administration of DEX (2.5 mg/kg/day) was used for the induction of OS in the rats. The rats were received the oral administration of aromadendrin (2.5, 5 and 10 mg/kg) and alendronate for 20 weeks. The body weight, organ weight, transverse diameter, bone length, microcomputed tomography (MicroCT) parameters, oxidative stress parameters, inflammatory cytokines, caspase parameters, inflammatory parameters and messenger ribonucleic acid (mRNA) expression were estimated. Aromadendrin treatment improved the body weight and altered the organ weight (vagina, uterus, and femoral weight); bone weight, transverse diameter, bine length, bone mineral density and bone mineral content level. Aromadendrin altered the level of MicroCT parameters, bone parameters (osteocalcin [OC], border gateway protocol, tartrate-resistant acid phosphatase, beta-CrossLaps, alkaline phosphatase, acid phosphatase); nutrient (phosphorus, magnesium, calcium, 1,25(OH)2-vitamin D3); hormone level (calcitonin, parathyroid hormone, E2), oxidative stress, inflammatory cytokines, inflammatory parameters (nuclear factor-κB [NF-κB], C-reactive protein, monocyte chemoattractant protein-1); caspase parameters (caspase-3, caspase-8, caspase-9), receptor activator of nuclear factor B ligand (RANKL), Osteoprotegerin (OPG), and OPG/RANKL ratio, respectively. Aromadendrin treatment altered the mRNA expression of RANKL, OPG, OPG/RANKL ratio. Aromadendrin exerts an anti-OS effect against DEX-induced OS in rats via alteration of NF-κB and RANKL/OPG signaling pathway.

PMID 42969984
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about zolpidem tartrate